Back
Cartesian Therapeutics, Inc. 10K Form
Sell
37
RNAC
Cartesian Therapeutics, Inc.
Last Price:
$6.90
Seasonality Move:
7.79%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive RNAC News And Ratings
See the #1 stock for the next 7 days that we like better than RNAC
RNAC Financial Statistics
Sales & Book Value
| Annual Sales: | $38.9M |
|---|---|
| Cash Flow: | $-20.1M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-1.38 |
| Price / Book: | 568.21 |
Profitability
| EPS (TTM): | -2.59000 |
|---|---|
| Net Income (TTM): | $-61.9M |
| Gross Margin: | $37.8M |
| Return on Equity: | 0% |
| Return on Assets: | -15.68% |
Cartesian Therapeutics, Inc. Earnings Forecast
Key Cartesian Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 11 years for RNAC is 97.04%.
-
The Selling, General & Administrative Expenses for RNAC have been equal to 77.42% of Gross Profit Margin.
-
The Research & Development expenses have been 115.40% of Revenue.
-
The Net Earning history of RNAC is -198.97% of Total Revenues.
-
Per Share Earnings over the last 11 years have been positive in 7 years.
Cartesian Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RNAC |
| Website: | cartesiantherapeutics.com |
Debt
| Debt-to-Equity Ratio: | -0.35 |
|---|---|
| Current Ratio: | 10.67 |
| Quick Ratio: | 10.44 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RNAC Technical Analysis vs Fundamental Analysis
Sell
37
Cartesian Therapeutics, Inc. (RNAC)
is a Sell
Is Cartesian Therapeutics, Inc. a Buy or a Sell?
-
Cartesian Therapeutics, Inc. stock is rated a SellThe current Cartesian Therapeutics, Inc. [RNAC] share price is $6.90. The Score for RNAC is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.